PDF(Pubmed)
Abstract：
UNASSIGNED: To assess the effects of COVID-19 pandemic on the epidemiology of neonatal sepsis and the antibiotic resistance profiles of pathogens involved.
UNASSIGNED: This retrospective cohort study analyzed infants diagnosed with culture-proven sepsis at the neonatal department of a tertiary children\'s hospital in East China from January 2016 to December 2022. We compared the clinical and microbiological characteristics of neonatal sepsis cases between the pre-pandemic Phase I (2016-2019) and during the COVID-19 pandemic Phase II (2020-2022).
UNASSIGNED: A total of 507 infants with 525 sepsis episodes were included, with 343 episodes in Phase I and 182 in Phase II. The incidence of early-onset sepsis (EOS) was significantly lower during Phase II (p < 0.05). Infants in Phase II had lower gestational ages and birth weights compared to Phase I. Clinical signs such as mottled skin, severe anemia, thrombocytopenia were more prevalent in Phase II, alongside a higher incidence of complications. Notably, necrotizing enterocolitis (NEC) (p < 0.05) and meningitis (p < 0.1) occurred more frequently during Phase II. Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) were the predominant pathogens isolated from infants of death and cases with complications. A significant decrease in the proportion of K. pneumoniae was observed in Phase II, alongside increased antibiotic resistance in both E. coli and K. pneumoniae. The period of the COVID-19 pandemic (Phase II) was identified as an independent risk factor for complications in infants with neonatal sepsis.
UNASSIGNED: COVID-19 pandemic response measures correlated with a decrease in EOS and an increase in neonatal sepsis complications and antibiotic resistance.
UNASSIGNED: This retrospective cohort study analyzed infants diagnosed with culture-proven sepsis at the neonatal department of a tertiary children\'s hospital in East China from January 2016 to December 2022. We compared the clinical and microbiological characteristics of neonatal sepsis cases between the pre-pandemic Phase I (2016-2019) and during the COVID-19 pandemic Phase II (2020-2022).
UNASSIGNED: A total of 507 infants with 525 sepsis episodes were included, with 343 episodes in Phase I and 182 in Phase II. The incidence of early-onset sepsis (EOS) was significantly lower during Phase II (p < 0.05). Infants in Phase II had lower gestational ages and birth weights compared to Phase I. Clinical signs such as mottled skin, severe anemia, thrombocytopenia were more prevalent in Phase II, alongside a higher incidence of complications. Notably, necrotizing enterocolitis (NEC) (p < 0.05) and meningitis (p < 0.1) occurred more frequently during Phase II. Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) were the predominant pathogens isolated from infants of death and cases with complications. A significant decrease in the proportion of K. pneumoniae was observed in Phase II, alongside increased antibiotic resistance in both E. coli and K. pneumoniae. The period of the COVID-19 pandemic (Phase II) was identified as an independent risk factor for complications in infants with neonatal sepsis.
UNASSIGNED: COVID-19 pandemic response measures correlated with a decrease in EOS and an increase in neonatal sepsis complications and antibiotic resistance.
摘要：
■评估COVID-19大流行对新生儿败血症流行病学的影响以及所涉及病原体的抗生素耐药性。
■这项回顾性队列研究分析了2016年1月至2022年12月在华东地区某三级儿童医院新生儿科诊断为文化证实的败血症的婴儿。我们比较了大流行前I期（2016-2019年）和COVID-19大流行II期（2020-2022年）新生儿败血症病例的临床和微生物学特征。
■共纳入了507名患有525次败血症的婴儿，第一阶段343集，第二阶段182集。早发性败血症（EOS）的发生率在II期期间显着降低（p<0.05）。与第一阶段相比，第二阶段的婴儿的胎龄和出生体重较低。临床症状，如斑驳的皮肤，严重贫血,血小板减少症在II期更为普遍，并发症发生率较高。值得注意的是,坏死性小肠结肠炎（NEC）（p<0.05）和脑膜炎（p<0.1）在II期发生频率更高。大肠杆菌(E.大肠杆菌)和肺炎克雷伯菌(K.肺炎）是从死亡婴儿和并发症病例中分离出的主要病原体。在II期观察到肺炎克雷伯菌比例显着下降，大肠杆菌和肺炎克雷伯菌的抗生素耐药性增加。COVID-19大流行期（II期）被确定为新生儿败血症婴儿并发症的独立危险因素。
■COVID-19大流行应对措施与EOS下降、新生儿败血症并发症和抗生素耐药性增加相关。
■这项回顾性队列研究分析了2016年1月至2022年12月在华东地区某三级儿童医院新生儿科诊断为文化证实的败血症的婴儿。我们比较了大流行前I期（2016-2019年）和COVID-19大流行II期（2020-2022年）新生儿败血症病例的临床和微生物学特征。
■共纳入了507名患有525次败血症的婴儿，第一阶段343集，第二阶段182集。早发性败血症（EOS）的发生率在II期期间显着降低（p<0.05）。与第一阶段相比，第二阶段的婴儿的胎龄和出生体重较低。临床症状，如斑驳的皮肤，严重贫血,血小板减少症在II期更为普遍，并发症发生率较高。值得注意的是,坏死性小肠结肠炎（NEC）（p<0.05）和脑膜炎（p<0.1）在II期发生频率更高。大肠杆菌(E.大肠杆菌)和肺炎克雷伯菌(K.肺炎）是从死亡婴儿和并发症病例中分离出的主要病原体。在II期观察到肺炎克雷伯菌比例显着下降，大肠杆菌和肺炎克雷伯菌的抗生素耐药性增加。COVID-19大流行期（II期）被确定为新生儿败血症婴儿并发症的独立危险因素。
■COVID-19大流行应对措施与EOS下降、新生儿败血症并发症和抗生素耐药性增加相关。
